Treatment Options in Newly Diagnosed Multiple Myeloma

Insight From: Noopur Raje, MD, Dana-Farber; Sagar Lonial, MD, Winship, and
Ann McNeill, RN, APN, JTCC
Published Online: Monday, August 4, 2014
For High-Definition, Click
Noopur Raje, MD, Sagar Lonial, MD, and Ann McNeill, RN, APN, describe the use of combination therapy for patients who are newly diagnosed with multiple myeloma. Raje remarks that therapy is selected based on transplant eligibility because some agents may not be appropriate for use in patients who receive autologous stem cell transplants. Raje and Lonial comment that patient eligibility for stem cell transplant depends on performance status.

Historically, the treatment of multiple myeloma involved the use of melphalan-based therapy, note Raje and Lional. However, recent data on combinations without melphalan have shown that lenalidomide/dexamethasone regimens without melphalan were as effective as melphalan-containing regimens; thus, there has been a shift toward the use of bortezomib/dexamethasone or lenalidomide/dexamethasone.

The goal of treatment is to achieve the best possible response, remarks Raje. The type of combination therapy used will depend on the patient’s tolerance for the medications; patients who are eligible for stem cell transplants may be able to tolerate 3-drug combination therapy, for example, with lenalidomide, bortezomib, and dexamethasone (VRD). Lonial remarks that carfilzomib may be used instead of bortezomib with dexamethasone and lenalidomide as part of a 3-drug regimen. McNeill states that at her practice site, the 2 most commonly used induction therapies are the VRD regimen and the bortezomib, cyclophosphamide, and dexamethasone (CyBorD) regimen.

Different strategies are needed for patients who are not eligible for transplant, notes Raje. Studies have shown that continuous treatment with lenalidomide/dexamethasone until progression was beneficial in patients not eligible for transplant.
View More From This Discussion
Episode 1 Imaging and Treatment Advances in Multiple Myeloma
Episode 2 High-Risk and Smoldering Multiple Myeloma
Episode 3 Treatment Options in Newly Diagnosed Multiple Myeloma
Episode 4 Treatment Decisions in Relapsed/Refractory Myeloma
Episode 5 Pomalidomide in Refractory Multiple Myeloma
Episode 6 Pomalidomide and Carfilzomib in Multiple Myeloma
Episode 7 Maintenance Therapy for Patients With Multiple Myeloma
Episode 8 Management of Adverse Events in Multiple Myeloma
Episode 9 Emerging Agents for Multiple Myeloma

Online CME Activities
Free CME from PER
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
Community Practice Connections: 15th Annual International Lung Cancer Congress®
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading